Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
2023-10-13 12:38:42 ET More on Roche Holding Roche: 2023 Should Mark The Bottom Roche: FX Drug But Positive Outlook Roche's Ocrevus' 10-year data shows MS drug cuts disability progression AbbVie blood cancer therapy fails in Phase 3 trial For further ...
2023-10-13 11:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A historically wide di...
– New data from Phase II FENopta study in relapsing multiple sclerosis (RMS) show fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to multiple sclerosis (MS) – – More than 90% relative reduction in new...
2023-10-13 04:57:44 ET More on Roche Roche: Positive Readouts From Pipeline Roche: 2023 Should Mark The Bottom Roche: FX Drug But Positive Outlook Ionis licenses two candidates to Roche for Alzheimer's, Huntington's U.S. govt. to restart program to sh...
– 10-year efficacy data highlight Ocrevus’ impact on preventing disability progression and maintaining mobility in both relapsing and progressive forms of multiple sclerosis (MS) – – 10-year safety data from over 6,000 patients continue to reinforce...
2023-10-11 13:14:41 ET More on Tempest Therapeutics Seeking Alpha’s Quant Rating on Tempest Therapeutics Historical earnings data for Tempest Therapeutics Financial information for Tempest Therapeutics For further details see: Tempest Therapeutics ...
– Black and Hispanic / Latinx people with multiple sclerosis (MS) often experience more severe disease and greater disability – – Results from the Phase IV CHIMES trial demonstrate safety and efficacy consistent with data from the Ocrevus Phase III studies –...
– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was comparable to IV infusion in providing rapid and sustained depletion of...
– Vabysmo showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous trials – – If approved by the FDA, RVO would be Vabysmo’s third indication in addition to wet age-related macular degeneration (AMD) and diabetic...
2023-10-09 19:30:05 ET Summary Merck's business has been dominated by its oncology drug Keytruda and HPV vaccine Gardasil, which have sustained its market share but are facing a reckoning in the not-too-distant future. They are slowly executing a pivot into adjacent areas of Oncol...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
Roche Holding Ltd ADR Website:
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-22 05:59:00 ET Both Pfizer (NYSE: PFE) and Roche Holdings (OTC: RHHBY) rank among the world's most powerful pharmaceutical companies. Yet neither is actively competing in the all-important market for weight loss drugs, which is currently being split between the likes...
– Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR) – – Safety data were consistent with the known safety profile for Susvimo in people...